Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091396 | 0.89 | P2RX7 (0.42) | P2RX7GRIN1GRIN2BEPHX2PTGES | |
| SCHEMBL6092264 | 0.88 | P2RX7 (0.42) | P2RX7GRIN1GRIN2BEPHX2PTGES | |
| SCHEMBL6092278 | 0.88 | P2RX7 (0.42) | P2RX7GRIN1GRIN2BEPHX2PTGES | |
| SCHEMBL6090143 | 0.83 | GRIN1 (0.41) | GRIN1GRIN2BPTGESMEN1KMT2A | |
| SCHEMBL6092269 | 0.83 | P2RX7 (0.41) | P2RX7GRIN1GRIN2BEPHX2MEN1 | |
| SCHEMBL6091931 | 0.83 | GRIN1 (0.41) | GRIN1GRIN2BPTGESMEN1KMT2A | |
| SCHEMBL6091938 | 0.83 | GRIN1 (0.41) | GRIN1GRIN2BPTGESMEN1KMT2A | |
| SCHEMBL6089685 | 0.82 | GRIN1 (0.44) | GRIN1GRIN2BPTGES | |
| SCHEMBL6091003 | 0.81 | MAPK1 (0.41) | GRIN1GRIN2BEPHX2PTGESMEN1 | |
| SCHEMBL6089960 | 0.81 | GRIN1 (0.39) | P2RX7GRIN1GRIN2BEPHX2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | IDO1, PTGS1, IDO2 | P2RX7 751/4885GRIN1 1424/4885GRIN2B 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.